Tumor stage at resection (N0 vs N+) · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy may leads to higher tumor stage at resection (N0 vs N+) compared with primary surgery (low certainty).
1 finding from 1 review
Postoperative morbidity RD · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
1 finding from 1 review
Postoperative mortality RD · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
1 finding from 1 review
Disease-free survival · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in disease‐free survival (landmark time 6 months) compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by type of data ‐ Individual patient data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by type of data ‐ Individual patient data compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by type of data ‐ Aggregated data · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to lower overall survival by type of data ‐ Aggregated data compared with primary surgery (moderate certainty).
1 finding from 1 review
Overall survival by tumor site ‐ Esophagus · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in overall survival by tumor site ‐ Esophagus compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by tumor site ‐ GE junction · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by tumor site ‐ GE junction compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by tumor site ‐ Stomach · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy showed no clear difference in overall survival by tumor site ‐ Stomach compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by chemo‐/radiotherapy ‐ Chemotherapy only · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by chemo‐/radiotherapy ‐ Chemotherapy only compared with primary surgery (high certainty).
1 finding from 1 review
Overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy probably leads to lower overall survival by chemo‐/radiotherapy ‐ Chemoradiotherapy compared with primary surgery (moderate certainty).
1 finding from 1 review
H. pylori persistence, regardless of regimen and dose · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H. pylori persistence, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PAN subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 10 days showed no clear difference in H. pylori persistence, PAN subgroup compared with 7 days (low certainty).
1 finding from 1 review
H. pylori persistence, PAQ subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 10 days may leads to lower H. pylori persistence, PAQ subgroup compared with 7 days (low certainty).
1 finding from 1 review
H. pylori persistence, PANi subgroup · patients with Helicobacter pylori infection
It is very uncertain whether PPI triple therapy for 10 days changes H. pylori persistence, PANi subgroup compared with 7 days (very low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 10 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 7 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, regardless of regimen and dose · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, regardless of regimen and dose compared with 10 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PCA subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days probably leads to lower H.pylori persistence, PCA subgroup compared with 10 days (moderate certainty).
1 finding from 1 review
H. pylori persistence, PAN subgroup · patients with Helicobacter pylori infection
PPI triple therapy for 14 days showed no clear difference in H.pylori persistence, PAN subgroup compared with 10 days (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · patients with Helicobacter pylori infection
PPI triple therapy for 14 days showed no clear difference in patients with adverse events, regardless of regimen and dose compared with 10 days (low certainty).
1 finding from 1 review